Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.
about
Current Therapy for Hypoplastic Left Heart Syndrome and Related Single Ventricle Lesions.Clinical research priorities in adult congenital heart diseaseFontan-associated protein-losing enteropathy and plastic bronchitis.Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.The failing Fontan: etiology, diagnosis and management.Late catheter interventions in hypoplastic left heart syndrome.New concepts: development of a survivorship programme for patients with a functionally univentricular heart.Protein-losing enteropathy and the Fontan operation.Plastic bronchitis in patients with fontan physiology: review of the literature and preliminary experience with fontan conversion and cardiac transplantation.Pulmonary vasodilator therapy in the failing Fontan circulation: rationale and efficacy.The Long-Term Management of Children and Adults with a Fontan Circulation: A Systematic Review and Survey of Current Practice in Australia and New Zealand.Low serum 25-hydroxyvitamin D levels and secondary hyperparathyroidism in Fontan patients.Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy.Administration of budesonide in children with graft-versus-host disease."Frontiers in Fontan failure: A summary of conference proceedings".Prevalence of Subclinical Enteric Alpha-1-Antitrypsin Loss in Children with Univentricular Circulation Following Total Cavopulmonary Connection.Oral budesonide as a therapy for protein-losing enteropathy in children after the Fontan operation.End-organ consequences of the Fontan operation: liver fibrosis, protein-losing enteropathy and plastic bronchitis.
P2860
Q30244119-CC482ADE-3F83-4EFF-B125-1AFE0A7D1093Q30418760-DFE189E9-09CC-42BE-A69E-A492F4FCADCBQ36044711-99E20266-7D52-4F1A-B789-B2494F5DDA38Q36261095-F650C54A-6D7B-46A3-B372-1B5141304D31Q37887563-75E0B13D-4F14-41A8-8E6C-ECF9E60D463BQ37895690-B9BD6441-B64E-45A8-B983-6ED69C4900BCQ37966105-45626DC0-45CB-4B44-9D89-7CE78B6EC205Q37966107-AC795872-26C7-473E-AF82-CFE176332311Q38003837-9AA532C9-12B6-4C94-BE2F-CAE6B5A469C6Q38117343-B5FABCFD-6A65-4A17-B7F2-40CB235F2EBFQ38671350-5662F671-65C1-4620-8A54-CC69B36BA084Q38804287-69293104-CCE7-42DB-9B1F-99541C8988D3Q40637231-43C17198-8334-4072-AFB1-BA9176F13DD4Q43457601-C37748CD-9853-42FE-8498-91D88A99B95DQ46519541-110F3651-D00B-409E-8419-E1F4F1FA96F8Q47663879-439E24C1-D03E-4C8A-805E-1A047649A4A9Q47844493-23837EE1-7EB7-48A1-AC11-34A9BDD98B8DQ51719726-4E32C509-661F-4606-8F69-821BCDC48074Q51760263-924FEF3B-9E9A-4291-BC58-0BCE62A987EE
P2860
Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Use of oral budesonide in the ...... hy after the Fontan operation.
@en
Use of oral budesonide in the ...... hy after the Fontan operation.
@nl
type
label
Use of oral budesonide in the ...... hy after the Fontan operation.
@en
Use of oral budesonide in the ...... hy after the Fontan operation.
@nl
prefLabel
Use of oral budesonide in the ...... hy after the Fontan operation.
@en
Use of oral budesonide in the ...... hy after the Fontan operation.
@nl
P2093
P1476
Use of oral budesonide in the ...... hy after the Fontan operation.
@en
P2093
Akash Patel
David J Goldberg
Deepika Thacker
Edisio Semeao
Jack Rychik
Kathryn Dodds
P304
P356
10.1016/J.ATHORACSUR.2009.09.063
P407
P577
2010-03-01T00:00:00Z